Protein Kinase Inhibitors: all 15,766 studies that test it
Page 19 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLNot yet recruitingNCT05931757Phase 2
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingNCT05931393Phase 2
- A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in OsteosarcomaRecruitingNCT05926492Phase 2
- Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
- Sirolimus in the Treatment of Refractory/Relapsed wAIHARecruitingNCT05925023Not applicable
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
- Zanubrutinib in the Treatment of Relapsed/Refractory wAIHARecruitingNCT05922839Phase 2
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade GliomaRecruitingNCT05917145Phase 1
- Ruxolitinib as GVHD Prophylaxis in AA PatientsNot yet recruitingNCT05914714Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric CancerNot yet recruitingNCT05914610Phase 3
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.Not yet recruitingNCT05914584Phase 2/3
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Phase 2
- Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast CancerRecruitingNCT05910398Phase 3
- Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingNCT05910034Phase 2
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingNCT05905887Phase 2
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingNCT05904457Phase 2
- Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseRecruitingNCT05904093Phase 1
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
- Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes MellitusRecruitingNCT05902468Phase 2/3
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT05900921Phase 2
- Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNot yet recruitingNCT05900219Phase 2
- Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
- Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTRecruitingNCT05896007Phase 2
- Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver MetastasesNot yet recruitingNCT05894837Phase 2
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingNCT05894239Phase 3
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingNCT05887726Phase 2
- Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
- c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene AberrationRecruitingNCT05882292Phase 2
- Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast CancerRecruitingNCT05880927Phase 2
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Not yet recruitingNCT05876832Phase 3
- Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsRecruitingNCT05876806Phase 2
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingNCT05874414Phase 1/2
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeRecruitingNCT05873712Phase 2
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.RecruitingNCT05872347Phase 2
- Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerRecruitingNCT05872204Phase 2
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
- Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKIRecruitingNCT05869162Phase 2
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingNCT05867329Phase 4
- A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT05866692Phase 1
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerRecruitingNCT05866510Phase 2
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingNCT05865132Phase 2
- The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBCNot yet recruitingNCT05862610Phase 2
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Phase 3
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05860465Phase 2/3
- A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2
- Correction of Psoriatic T Cell Signatures by DeucravacitinibRecruitingNCT05858645Phase 4
- Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Phase 3
- Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
- Inflammation and Depression in People With HIVRecruitingNCT05849038Phase 2
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Phase 2
- Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal SarcomaEnrolling by invitationNCT05844813Phase 4
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingNCT05843253Phase 2
- Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
- Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerNot yet recruitingNCT05841381Phase 3
- The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05839275Phase 1/2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- Pyrotinib in Women With High-risk in Early Stage Breast CancerRecruitingNCT05834764Phase 2
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.RecruitingNCT05833763Phase 2
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingNCT05832892Phase 1/2
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2
- Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaRecruitingNCT05830500Phase 4
- A Phase I Study of QLS12004 in Patients With Advanced Solid TumorsNot yet recruitingNCT05829616Phase 1
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruitingNCT05828069Phase 2
- Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingNCT05823987Phase 2
- Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingNCT05823623Phase 2
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3
- Avapritinib in CBF-AML With KIT MutationsRecruitingNCT05821738Phase 2
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingNCT05820841Phase 3
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingNCT05818982Phase 2
- Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingNCT05818267Not applicable
- Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNRecruitingNCT05817955Phase 2
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsRecruitingNCT05817903Phase 2
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingNCT05817214Phase 2
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLCEnrolling by invitationNCT05813522Phase 2
- Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
- Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated GliomasRecruitingNCT05804227Early Phase 1
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RDRecruitingNCT05781516Not applicable
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
- Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingNCT05778149Phase 2
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Phase 1/2
- A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCRecruitingNCT05775874Phase 2
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingNCT05774899Phase 1/2
- A Study of XZB-0004 in Patients With Solid TumorsRecruitingNCT05772455Phase 1